Goodwin
Kingsley L. Taft
- Deals
- 4
- Latest
- Jun 2026
- Most deals in
- Biotech
Firm
- Goodwin Law firm · 2026 · 4 deals
Often works with
- Sarah Solomon 3 deals together
- Arman Oruc 3 deals together
- Gozde Guckaya 3 deals together
- Timothy Holahan 2 deals together
- Malhar Naik 2 deals together
- Julie Tibbets 2 deals together
- Kevin Walsh 2 deals together
- Matthew Dunay 2 deals together
Deals
Deals dated after 30 September 2026 are still being collected.
Columns
| Jun 2026 | Parabilis Medicines | – | – | Placement | Legal adviser to the issuer | Completed | 75.0 | Biotech+1 | Parabilis Medicines placement |
| Apr 2026 | Tubulis | EQT Life Sciences (LSP 7 fund) | Gilead Sciences | Acquisition | Legal adviser to Tubulis (target) | Announced | 3,150.0 | Biotech+2 | Gilead Sciences acquisition of Tubulis |
| Mar 2026 | Ouro Medicines | – | Gilead | Acquisition | Legal adviser to Ouro Medicines (target) | Announced | 1,675.0 | Biotech+1 | Gilead acquisition of Ouro Medicines |
| Mar 2026 | Pikavation | Synnovation | Novartis | Acquisition | Legal adviser to Synnovation Therapeutics (seller) | Announced | 2,000.0 | Biotech+2 | Novartis acquisition of Pikavation |
Deals where Kingsley L. Taft is named on the firm's deal team, by the firm or the press.